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Abstract
Introduction: There are currently 23 missense point mutations and one 4 basepair deletion
spanning different mitochondrial genes associated with mitochondrial encephalopathy, lactic
acidosis and stroke-like episodes (MELAS). The spectrum of mitochondrial DNA mutations in Arab
patients with MELAS is largely unknown.
Case presentation: A standard clinical examination was carried out on a 34-year-old Saudi
woman showing clinical features of MELAS. Fresh frozen muscle tissue was subjected to enzyme
histochemical analysis. DNA was extracted from her leukocytes and muscle tissue, and the full
mitochondrial genome was screened for base substitution mutations and deletions. Additionally,
we screened the polymerase gamma-1 nuclear gene for mutations. The patient was negative for the
most common m.3243 A>G MELAS mutation. Sequencing the full mitochondrial genome did not
reveal any known or potentially pathogenic sequence changes. The polymerase gamma-1 gene was
also free from mutations.
Conclusion: The clinical picture described here typically fits that observed in patients with MELAS
or mitochondrial stroke-like events, but mutations in recognized genes (mitochondrial DNA and
polymerase gamma-1 gene) were absent. We report the case of a patient with typical clinical
features of MELAS, but without an obvious genetic cause.
Introduction
Mitochondrial encephalopathy, lactic acidosis and stroke-
like episodes (MELAS) is a mitochondrial disorder typi-
cally associated with seizures and/or dementia with ele-
vated levels of cerebrospinal fluid (CSF) lactate. It is the
most common maternally inherited mitochondrial dis-
ease, with an A>G mutation at position 3243 in the
MTTL1 tRNALeu(UUR) of the mitochondrial DNA (mtDNA)
gene responsible for more than 80% of cases [1]. Cur-
rently, there are 23 missense point mutations and one 4
base pair (bp) deletion spanning different mitochondrial
genes that have been previously reported in association
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with MELAS (MITOMAP: http://www.mitomap.org). The
spectrum of mtDNA mutation in Arab patients with
MELAS is largely unknown, although one study has
reported a novel MTTL2 gene mutation in a Saudi boy
with typical clinical features of MELAS [2], highlighting
the fact that some MELAS patients who fulfill the tradi-
tional clinical criteria for MELAS could be negative for the
most common m.3243A>G mutation in this population.
In such cases, the patient should be screened for second-
ary mtDNA changes such as multiple mtDNA deletions
and for mutations in the mtDNA polymerase gamma
(POLG1) nuclear gene. Mutations in the POLG1 gene have
been implicated in a patient with MELAS [3]. In this study,
we describe a female patient with: i) typical clinical fea-
tures of MELAS; ii) absence of the MELAS m.3243A>G
common mutation or any other obvious mtDNA point
mutation; and iii) absence of any POLG1 mutation(s).
Case presentation
We have investigated the case of a 34-year-old Saudi
woman who presented with clinical symptoms suggestive
of MELAS. She was otherwise normal, able to finish col-
lege, had started work as a teacher and had married at the
age of 22. She was well until age 24 when she started to
have generalized tonic clonic seizures, which were suc-
cessfully controlled with anti-epileptic drugs. She lost her
vision at the age of 27 and then became deaf, and at the
age of 32, she developed right-sided weakness. At the age
of 33, she was admitted to hospital with abdominal pain
and tenderness, hypoactive bowel sound, vomiting, dehy-
dration and hypokalemia. The symptoms were highly sug-
gestive of pseudo-intestinal obstruction, which improved
with conservative measures. She reported no family his-
tory of a similar condition and her parents confirmed this.
She was underweight with a weight ranging from 33 to
34.5 kg and a height of 152 cm. Her serum lactate was ele-
vated at 3.8 mM (normal < 2 mM) as was her CSF lactate
at 4.5 mM.
Work-up initially showed a left occipital lobe infarction
followed by progressive decline in visual acuity and hear-
ing. Her seizures were controlled for 18 months with
lamotragine, but subsequent medication was discontin-
ued gradually. She then developed an episode of acute vis-
ual loss, generalized tonic clonic seizures and status
epilepticus, which was complicated by an aspiration
pneumonia for which she required admission to the
intensive care unit (ICU). Her general condition deterio-
rated rapidly, requiring ventilation support and a gastros-
tomy tube for feeding. She stayed in the ICU for
approximately 2 months during which she became very
wasted, spastic, mute, deaf, and blind. Cornea reflexes
were present and gag reflex absent.
A computed tomography (CT) brain scan showed bilat-
eral basal ganglia calcification and mild cerebellar atrophy
(Figure 1a). Her axial T2 brain magnetic resonance imag-
ing (MRI) scan showed a left temporo-parieto occipital
ischemic lesion (Figure 1b), which extended beyond the
typical vascular territory of the left middle cerebral artery
(Figure 1c). Magnetic resonance spectroscopy (MRS)
showing inversion of the J-coupling phenomenon at 1.3
ppm indicating a lactate peak (Figure 1d).
The patient consented to a muscle biopsy, which was sub-
jected to enzyme histochemical analysis as previously
described [4]. Modified Gomori trichrome stain revealed
ragged red fibers (Figure 2a) and cytochrome c oxidase
(COX) staining showed abnormal accumulation of
brownish staining indicating accumulation of mitochon-
dria (Figure 2b). Succinate dehydrogenase (SDH) staining
showed a few ragged blue fibers and intense staining in
the mitochondria of the blood vessels, a feature com-
monly seen in MELAS cases (Figure 2c).
Electron microscopy showed an abnormal collection of
mitochondria with paracrystalline inclusions, osmi-
ophilic inclusions and mitochondrial vacuoles (Figure
2d). While analysis of respiratory chain enzymes in the
muscle was not possible, we decided to pursue the under-
lying genetic defect based on the mitochondrial histo-
chemical changes we observed, which were diagnostic of
an underlying mtDNA genetic abnormality.
Skeletal muscle DNA was used to determine the sequence
of the entire mtDNA coding region, but we did not detect
any reported pathological or potentially pathological
sequence changes.
Recent findings of mutations in the nuclear-encoded gene
encoding the catalytic subunit of the mtDNA polymerase
gamma-1 (POLG1) gene [3] promoted us to screen this
gene for mutations but no pathogenic mutation was iden-
tified. The absence of mutations within the mtDNA and
the POLG1 gene prompted further investigation into sec-
ondary mtDNA changes.
Discussion
The m.3243A>G common MELAS mutation is responsi-
ble for more than 80% of reported MELAS cases [1]. Most
of these reports came from western countries. However,
more than 85% of the DNA samples sent to the Molecular
Diagnostic Laboratory at King Faisal Specialist Hospital
from Arab patients with typical clinical features of MELAS
were negative for the m.3243A>G common MELAS muta-
tion (personal observation). In support of this, we previ-
ously reported a novel MTTL2 gene mutation in a Saudi
boy with typical clinical features of MELAS [2]. Addition-
ally, we have reported a different pattern of mutations inJournal of Medical Case Reports 2009, 3:77 http://www.jmedicalcasereports.com/content/3/1/77
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a group of Arab patients with typical clinical features of
Leber's Hereditary Optic Neuropathy (LHON). In western
countries, the three primary LHON mutations were
detected in > 90% of LHON cases, while only 17% of Arab
LHON patients had one of the three LHON mutations.
The remaining 83% had different mtDNA mutations or
other types of mitochondrial abnormalities [5]. These
findings highlight a possible variability in the mtDNA
mutation pattern among patients from different ethnici-
ties with the same disease. This observation, and the fact
that mitochondrial disorders are clinically variable disor-
ders, make it a challenge to draw reasonable phenotype-
genotype correlations. Having said that, the typical clini-
cal features observed among Arab patients with MELAS
are not different from those observed in western countries
[6] and the variability is only limited to the spectrum of
mutations detected. Our previous findings in the LHON
study [5] support this hypothesis.
The patient described here had clinical symptoms sugges-
tive of MELAS. This was supported by her neuroimaging
presentation, histochemical analysis, high serum and CSF
lactate levels and electron microscopic results from her
muscle tissues. Genetics analysis of her DNA indicated
that she was negative for the m.3243A>G common
MELAS mutation and screening of her entire mtDNA
genome did not reveal any reported pathogenic or poten-
tially pathogenic mtDNA mutation. When we screened
the entire mitochondrial genome of this patient, we
ignored any DNA variant not resulting in an amino acid
(a) A computed tomography brain scan showing bilateral basal ganglia calcification; the cerebellum shows prominent folia indi- cating mild cerebellar atrophy Figure 1
(a) A computed tomography brain scan showing bilateral basal ganglia calcification; the cerebellum shows 
prominent folia indicating mild cerebellar atrophy. (b) Axial T2 brain magnetic resonance image scan showing left tem-
poro-parieto occipital ischemic lesion. (c) Axial T2 brain magnetic resonance image scan showing the extension of the parietal 
temporal region to the occipital lobe, and also showing a right occipital lesion. (d) Magnetic resonance spectroscopy showing 
inversion of J-coupling phenomenon at 1.3 ppm, indicating lactate peak.Journal of Medical Case Reports 2009, 3:77 http://www.jmedicalcasereports.com/content/3/1/77
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change (synonymous nucleotide changes) and this is the
current practice in medical genetics. Nowadays, however,
numerous DNA variants that are not associated with an
amino acid change have been shown to have deleterious
effects [7]. Because of this, we could possibly have missed
the causal mtDNA base substitution. Recent findings of
mutations in the nuclear-encoded gene encoding the cat-
alytic subunit of the mtDNA polymerase gamma (POLG1)
[3], prompted us to screen this gene for mutations but no
pathogenic mutations were identified after sequencing the
entire gene. We cannot of course ignore the contribution
of other nuclear genes encoding proteins responsible for
stability and structural components of the mtDNA or to
the oxidative phosphorylation (OXPHOS) machinery
being involved in the pathogenesis of MELAS-like disease.
Conclusion
We report a patient with typical clinical features of MELAS
but without an obvious genetic cause.
(a) Modified Gomori trichrome stain showing several ragged red fibers (arrowhead) Figure 2
(a) Modified Gomori trichrome stain showing several ragged red fibers (arrowhead). (b) Cytochrome c oxidase 
stain showing Type-1 lightly stained and Type II fibers, darker fibers, and a few fibers with abnormal collections of mitochondria 
(arrowhead). Note cytochrome c oxidase negative fibers as usually seen in mitochondrial encephalopathy, lactic acidosis and 
stroke-like episodes (MELAS). (c) Succinate dehydrogenase staining showing a few ragged blue fibers and intense staining in the 
mitochondria of the blood vessels (arrow). (d) Electron microscopy showing abnormal collection of mitochondria with 
paracrystalline inclusions (arrowhead), osmiophilic inclusions (large arrowhead) and mitochondrial vacuoles (small arrowhead).Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Medical Case Reports 2009, 3:77 http://www.jmedicalcasereports.com/content/3/1/77
Page 5 of 5
(page number not for citation purposes)
Abbreviations
COX: cytochrome c oxidase; CSF: cerebrospinal fluid; CT:
computed tomography; ICU: intensive care unit; MELAS:
mitochondrial encephalopathy, lactic acidosis and stroke-
like episodes; MRI: magnetic resonance imaging; MRS:
magnetic resonance spectroscopy; mtDNA: mitochon-
drial DNA; OXPHOS: oxidative phosphorylation; PCR:
polymerase chain reaction; POLG1: polymerase gamma-1;
SDH: succinate dehydrogenase.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KKA was in charge of design, analysis of data and overall
supervision of the study. AH performed the technical
aspects of the study, PCR and sequencing. RWT performed
the sequencing of the POLG1 and wrote part of the man-
uscript. SB and HD were responsible for recruiting the
patient and the detailed clinical evaluation.
Consent
Written informed consent was obtained from the parents
of the patient for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Acknowledgements
KKA thanks the Glaucoma Research Chair at the Department of Ophthal-
mology, College of Medicine, King Saud University for their financial sup-
port. RWT thanks the Wellcome Trust, the Muscular Dystrophy 
Campaign, the Newcastle upon Tyne Hospitals Foundation NHS Trust and 
the Department of Health, UK (NCG Rare Mitochondrial Disorders of 
Adults and Children Service) for their continuing financial support.
References
1. Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG,
DeVivo DC, DiMauro S, Rowland LP: MELAS: an original case
and clinical criteria for diagnosis.  Neuromuscul Disord 1992,
2(2):125-135.
2. Abu-Amero KK, Ozand PT, Al-Dhalaan H: Novel mitochondrial
DNA transversion mutation in transfer ribonucleic acid for
leucine 2 (CUN) in a patient with the clinical features of
MELAS.  J Child Neurol 2006, 21(11):971-972.
3. Deschauer M, Tennant S, Rokicka A, He L, Kraya T, Turnbull DM,
Zierz S, Taylor RW: MELAS associated with mutations in the
POLG1 gene.  Neurology 2007, 68(20):1741-1742.
4. Kollberg G, Moslemi AR, Lindberg C, Holme E, Oldfors A: Mito-
chondrial myopathy and rhabdomyolysis associated with a
novel nonsense mutation in the gene encoding cytochrome
c oxidase subunit I.  J Neuropathol Exp Neurol 2005, 64(2):123-128.
5. Abu-Amero KK, Bosley TM: Mitochondrial abnormalities in
patients with LHON-like optic neuropathies.  Invest Ophthalmol
Vis Sci 2006, 47(10):4211-4220.
6. Hirano M, Pavlakis SG: Mitochondrial myopathy, encephalopa-
thy, lactic acidosis, and strokelike episodes (MELAS): cur-
rent concepts.  J Child Neurol 1994, 9(1):4-13.
7. Cartegni L, Chew SL, Krainer AR: Listening to silence and under-
standing nonsense: exonic mutations that affect splicing.  Nat
Rev 2002, 3(4):285-298.